Podcasts about Lyell

In this episode, Lyell K. Jones Jr, MD, FAAN, speaks with Aaron L. Berkowitz, MD, PhD, FAAN, who served as the guest editor of the February 2026 Neurology of Systemic Disease issue. They provide a preview of the issue, which publishes on February 2, 2026. Dr. Jones is the editor-in-chief of Continuum: Lifelong Learning in Neurology® and is a professor of neurology at Mayo Clinic in Rochester, Minnesota. Dr. Berkowitz is a Continuum® Audio interviewer and a professor of neurology in the Department of Neurology at the University of California, San Francisco, in San Francisco, California. Additional Resources Read the issue: continuum.aan.com Subscribe to Continuum®: shop.lww.com/Continuum Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @LyellJ Guest: @AaronLBerkowitz Full episode transcript available here Dr Jones: The human nervous system is so complex. You can spend your whole career studying it and still have plenty to learn. But the human brain does not exist in isolation. It's intricately connected with and reliant on other bodily systems. When those systems go awry, sometimes the first sign is in the nervous system. Today we will speak with Dr Aaron Berkowitz, an expert on the neurology of systemic disease, and learn a little about how these disorders can present and what we can do about it. Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about subscribing to the journal, listening to verbatim recordings of the articles, and exclusive access to interviews not featured on the podcast. Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum: Lifelong Learning in Neurology. Today, I'm interviewing Dr Aaron Berkowitz, who is Continuum's guest editor for our latest issue of Continuum on the neurology of systemic disease. Dr Berkowitz is a professor of clinical neurology at the University of California, San Francisco, and he has an active practice as a neurohospitalist and in outpatient general neurology---and, importantly, as a clinician educator. In addition to numerous teaching awards, Dr Berkowitz has published several books and also serves on our editorial board for Continuum. Dr Berkowitz, welcome. Thank you for joining us. Why don't you introduce yourself to our listeners?  Dr Berkowitz: Thanks, Lyell. As you mentioned, I'm a general neurologist and neurohospitalist here in San Francisco, California at UCSF and very involved in resident education as well. And I was honored, flattered and a little bit frightened when I received the invitation to guest edit this massive issue on the neurology of systemic disease. But I've learned a ton, and it's been great to work with you and the incredible authors we recruited to write for us. And I'm excited to have the issue out in the world.  Dr Jones: Yeah, me too. And you and I have talked about it before: you're one of a very small group of people who have guest edited multiple issues on different topics, right?  Dr Berkowitz: That's right. I did the neuroinfectious disease issue in… was it 2020? 2021? Something like that.  Dr Jones: Yeah. So, congratulations, more people have walked on the moon than done what you've done. And I'm looking forward to chatting, Aaron, and really grateful for your work putting together a fantastic issue. I think our listeners will appreciate that the nervous system does not function in isolation. It's important to understand the neurologic manifestations of diseases that originate within the brain, spinal cord, nerves, muscles, etc., but also the manifestations of diseases that begin in other systems and, you know, may masquerade as a primary neurologic disorder. So, it's obviously an important topic for neurologists, since many of these patients are receiving care in another setting, perhaps from another specialist. I almost think of this issue of Continuum as a handbook for the consultant neurologist, inpatient or outpatient. I don't know. Do you think that's a fair characterization of the topic? Dr Berkowitz: Absolutely. I completely agree with you. I think, yeah, many of us go into neurology interested in our primary diseases, whether it's stroke or Parkinson's or neuropathy or particular interest in neurologic symptoms, whether they're cognitive, motor, sensory, visual. And we quickly learn in residency, right? As you said, a lot of what we see is neurologic manifestations of primary diseases. So, I don't know how similar this is to other training programs. But it seemed like, if I'm remembering correctly, my first year of residency was mostly on primary neurology services, general stroke, ICU. And we moved into the consultant role more in the PGY-3 year the next year. And I remember explaining to students rotating with us on the consult services, this is actually much more complex in a way, because the patient has some type of symptom in a much broader and much more complicated context of multiple things going on. And I call it "neurology in the wild." There's, like, neurology of, this patient's had a stroke and we know they have a stroke and we're trying to figure out why and treat it. That's all interesting. But our question here, is there a stroke needle buried in this haystack of all of these medical or surgical complications? And learning what I call neurology of X, which is really what this issue is; as you said, that there's a neurology of everything. There's a neurology of cardiac disease. There's a neurology of the peripartum. There's a neurology of rheumatologic disease. There's every new treatment that comes out in oncology has a neurology we learn, right? There's a neurology of everything.  Dr Jones: There's a lot of axes, right? There's the heart-brain axis and the kidney-brain axis. And… I think we cover everything except the spleen-brain axis, which maybe that's a thing, maybe not. I'll probably hear from all the spleen fans out there. So, I want to do a little bit of an experiment. We're going to do something new today on the podcast. Before we get into the questions, we're going to start with a Continuum Audio trivia question. So, this will be a first time ever. Dr Berkowitz, we all know that chronic hyperglycemia, or diabetes, can lead to many neurologic and systemic complications and that optimal glucose control is our goal. For our listeners, here's the question: what neurologic complication can occur from correcting hyperglycemia too quickly? What neurologic complication can occur from correcting hyperglycemia too quickly? Stick around to the end of our interview for the answer. So, Aaron, let's get right to it. You had a chance to review all the articles in this issue on the neurology of systemic disease. What do you think in all of those is the most exciting recent development for patients who fit into this category? Dr Berkowitz: Yeah, that's a great question. I think we talked about when we were putting this issue together, right, a lot of the Continuum subspecialty topics; there should have been updates on particular disease diagnostics, treatments, new phenotypes. Whereas here probably a lot less has changed in primary heart disease, primary cancer. As I'd like to say to our students trying to excite them about neurology, most specialties have new treatments, but I can name a large number of new diseases, right, that have been discovered since we've been out of training. So, a lot of the primary medicine stays the same, and the neurologic complications stay the same. But probably the thing that many readers will want to keep handy and will probably be much in need of update again in three years are the neurologic complications of all the new cancer treatments. So, if we think back to I finished training just over ten years ago when a lot of the fill-in-the-blank-umabs were coming out, CAR T therapy, and we were starting to see a lot of neurology, I remember, related to these and telling the oncologists and they said, oh, you just wait. We are seeing at the conferences that there's a lot of neurology to these. And I feel like that is always a moving target. And I think we are seeing a lot of those and it's hard to keep up with which treatments can cause which complications, which syndromes and which severities require holding the treatment when you can rechallenge longer-term complications of CAR T cell therapies now that we've learned more about the acute complications. So, Amy Pruitt from Penn has written us a fantastic article for this issue that covers a lot of the updates there. And I learned a lot from that. I feel like that's the one that just like every time the carnioplastic diseases are reviewed in Continuum, it seems like the table is another page longer from your colleagues there in Rochester teaching us about new antibodies. And I feel like, for this issue, that's one of the areas that felt like there was a lot of very new content to keep up with since last time.  Dr Jones: That's good news, right? It's good that we have new immunotherapies for cancer, but it does lead to neurologic catastrophes sometimes, and it is a moving target, really rapid. So, you mentioned that just over ten years ago you finished your training and now we see a lot more of these complex immunotherapy-related neurologic complications. What about in the other direction? Are there any things that you see less commonly now in your practice than you might have seen ten years ago right when you were finishing training?  Dr Berkowitz: I would say no, I think. I think we're seeing a lot of new stuff, and we're still seeing a high volume of the classic consults we tend to get, whether that's altered mental status in a patient who's systemically ill; weakness or difficulty reading from the ventilator in a patient who's critically ill; patient has endocarditis and has a stroke hemorrhage or mycotic aneurysm, what do we do? Yeah, one of the parts that was really fun and educational editing this issue is, I really wanted to ask the experts the questions I find that are really troubling and challenging and make sure we could understand their perspective on things like the endocarditis consult, which I always feel like each time there's some twist that even though the question is what do we do about this stroke and/or hemorrhage and/or aneurysm and is surgery safe? It seems like each time I always feel like I'm reinventing the wheel, trying to really sort out how to think about this. And we have a great article from Alvin Doss at Beth Israel and Steve Feskey from Boston Medical Center. It covers a lot of cardiology, as you know, in that article about a great section on endocarditis where every time it came back for review, I would say, but what about this? This comes up. What about this? Can you explain how you think about this for our readers? I don't know. I'd be curious to hear your perspective. It sounds like we agree on what has become more common. I don't think anything in neurology seems to become less… Dr Jones: Well, no, I guess we haven't really solved anything, I guess we haven't cured any problem. But that's okay, right? I mean, it's building on an established foundation of experience and history in our field. And you know, we mentioned earlier that in many ways this issue is kind of like a neurology consultant's handbook. We did something a little different with it in that sense. In addition to you serving as the guest editor, you have authored an article in the issue. It touches on something that we've talked about a couple of times, and I'd be interested to hear you talk through it with our listeners a little bit on how to approach the neurologic consultation. Tell us a little more about that and your article and how you approached it.  Dr Berkowitz: Oh, yeah, thanks. Well, thanks first of all for inviting me to think about a sort of introductory article to this issue. And I was trying to think about what to write about because, as you've said and we've been talking about, no one could know every neurologic complication of every medical disease, treatment, surgery, hospital context. Probably many of us don't even know all the muscle diseases, right, within neurology. So how could we know all this stuff? And we need some type of manual from our colleagues that can explain, okay, I know this patient has inflammatory bowel disease and they've had a stroke. Is that- are these related? Are these unrelated? And I thought the articles kind of answer all of these questions. What would I say beyond this patient has disease X and is on drug Y? Well, look up in this issue disease X and see what the neurology can be, common and rare and how often it's associated, how often it's the presenting feature, how often it means the treatment is failing, etc. I thought, I'm not sure there's much to say there. That's about a paragraph. And I thought, well, let's think even more broadly about neurologic consultation. And as you know, I like to think about diagnostic reasoning and clinical reasoning. And we talk a lot about framing bias right? And I think that is very common in consultative neurology because we'll be told in the consult or in the page or E-consult or whatever it is, this is a blank-year-old blank with a history of blank on treatment blank. And right away your mind is starting to say, oh, well, the patient just had heart disease, or, the patient is nine months pregnant, or, the patient is on an immune checkpoint inhibitor. And whether you want to do it or not, your mind is associating the patient's neurology with that. And it's- even if we know we're framing or anchoring, it's hard to kind of pull away from that. And most of the time, common things being common, a patient with cancer develops new neurology, It's probably the cancer, the treatment, or sometimes a paraneoplastic syndrome. But I've definitely found if you do a lot of inpatient neurology and a lot of consults that you're seeing so much and you have no choice but to apply these heuristics, because you're seeing a lot of volume quickly and the patients are in the hospital or they're being closely followed and outpatient setting by another specialist. You presume if you didn't get it quite right the first time, it's going to come back to you. And there's a little bit of difficulty figuring out, this is a case, actually, of all the altered mental status in acutely ill patients I got today, this is the one I should dig deeper in that I think this could turn out to be a stroke or encephalitis as opposed to delirium. I felt like that I really haven't approached that except knowing that it's easy to fall into traps. And so, I started to think about framing bias. You know, we talked about if we become aware of our biases, right, we're better at not falling prey to them. But it's subconscious. So, we might be applying it without even realizing, or even saying, I might be framing this case the wrong way, you can go right on framing it the wrong way. So, I want to kind of get a little more granular on what types of framing biases actually are relevant, specifically, to the console setting. And so, I tried to come up with a few more specific examples and try to think about ways that we could at least have a quick, if our knee-jerk is to associate primary disease X that the patient has or primary treatment X with neurologic symptom Y, what's at least a quick counter-knee jerk to say, what if it could be something else? So, for example, one of them I call "low signal-to-noise ratio bias." Altered mental status in the acutely ill hospitalized patient. What would you say, Lyell? 99 out of 100- 99.9 out of 100, it's not a primary neurologic disease. Is that fair to say? Dr Jones: Very high, yep. I agree. Dr Berkowitz: Yeah. But could it be a stroke? Could it be non-convulsive status epilepticus, meningitis encephalitis? So, how do we sort of counteract low signal-to-noise ratio bias, acknowledging it exists, acknowledging most of the time there is a low signal-to-noise, that it's not going to be neurology---to just for example, use the time course. This is pretty acute. Have I convinced myself this is not a stroke or a seizure or an acute neurologic infection? And if I'm not sure at the bedside, should I err on the side of more testing? Or the "curbside bias," as I call when your colleague just sends you a text message on your phone, No need to even open the chart, Dr Jones. Patient had a cerebellar stroke. Incidental. They're here for something else. Aspirin, right? Just like a super tentorial stroke. And you might reply thumbs up. And then imagine you open the CT scan and it's a huge cerebellar stroke with fourth ventricular compression- and patient can hide a lot of stroke back there, might just have a little ataxia. You were curbsided and that framed you to think, oh, they asked me, is aspirin okay for a cerebellar stroke and I said yes, without realizing actually the question should have been posed is, how do you manage a huge stroke with mass effect in the posterior fossa? So, these types of biases, I come up with five of them, I won't go through all of them. I'm in the article to sort of acknowledge for the reader, most of the time it's going to be what you look up in this issue, but how to think about the times where it might not be and how to be more precise about what framing is and different types of framing that occur specifically in the consultant arena. Dr Jones: And I think the longer we practice, the more of those low-frequency exceptions that you see. And, you know, and then it sticks in our mind and sometimes the bias swings the other way; people, you know, think primarily about the low frequency. And so, it's tricky. And what I really enjoyed about that article, we started talking about this probably more than a year ago, and more than a year ago, I would say relatively few clinicians were using a now widely popular large language model for clinical decision-making; we won't name the model. And now I think most clinicians are using it almost every day, right? And I think it puts a premium on how to think and how to engage with the patient, and less about the facts and the lists that a lot of conventional medical education really is derived from. So, I really appreciate that article. We can pat ourselves in the back. We had some foresight to put it in the issue, and I think it's a great addition to it. Dr Berkowitz: Thank you. Dr Jones: So, the list of potential topics when we think about the neurologic manifestations of systemic disease, we tend to break it down by organ systems, right? But the amount of things that could end up in the issue is almost infinite. Is there anything that, when you were putting this issue together---either in terms of the topics or editing the articles---is there anything that you wanted to include, but we just didn't have room? Dr Berkowitz: I certainly won't say we covered everything, but I will say we were able to recruit a fantastic team of authors. And as you and I also talked about at the beginning, although you could say, we're doing the movement disorders issue, let's find all the top movement disorders folks who are expert specialists in this field, there's not really a neurohematologist or a neurogastroenterologist out here. So, you and I put our heads together to think of phenomenal general neurologists in most cases, some subspecialists who know a lot about this but were also excited to read a lot more about it and assemble the existing knowledge by the practicing neurologist for the practicing neurologist. And I think with that approach and letting folks have kind of, you know, I asked some specific questions. These are topics I hope you'll cover. These are vexing questions in this area. I hope you'll find some answers to how often can this neurology be the primary feature of this rheumatologic disease with no systemic manifestations and when should we look or as we mentioned, the complicated endocarditis consult. I won't say we covered everything. This could be, and is, textbook-sized, and there are textbooks on this topic. But I think on the contrary, authors came back and had sections on things that I might not have thought to ask- to cover. Dr Sarah LaHue, my colleague here at UCSF, I asked for an article, as traditionally in this issue, on the neurology of pregnancy in the postpartum state and included, I think probably for the first time in Continuum, a fantastic review of neurologic considerations in patients in menopause, which I'm not sure has been covered before. So, things that I wouldn't have even thought to ask for. Our authors came back with some fantastic stuff. And the ICU article by Dr Shivani Ghoshal, instead of focusing just on altered mental status in the ICU, weakness in the ICU---those are all in there---I also asked her to discuss complications of procedures in the ICU. How often do procedures in the ICU cause local neuropathies or vascular injury, these types of things. Dr Jones: Yeah, me too. And I guess that's a great advertisement, that there probably are things that we didn't cover, but if there are, we can't think of them. We've done as best as we can. So now let's come back to our Continuum Audio trivia question for our listeners. And I'll repeat the question: what neurologic complication can occur from correcting hyperglycemia too quickly? And I actually think there might be two correct answers to this one. Dr Berkowitz, what do you think? Dr Berkowitz: Yeah, I was thinking of two things. I hope these are the things you're thinking of as well. One is what I think used to be referred to as insulin neuritis, sort of an acute painful small fiber neuropathy from after the initiation of insulin, I think also called treatment-induced diabetic neuropathy or something of that nature. And then the other one described, defined and classified by your colleagues there in Rochester, the diabetic lumbosacral radiculoplexis neuropathy or Bruns-Garland syndrome or a diabetic amyotropy, I think, can also---if I'm not mistaken---also occur in this context; you should have weight loss in association with diet treatment of diabetes. But how did I do? Dr Jones: Yeah, you win the prize, the first-ever prize. There's no monetary value to the prize, but pride, I think, is a good one. Yeah, those were the two I was thinking of. The treatment-induced neuropathy of diabetes is really nicely covered in Dr Rafid Mustafa's article on the neurologic complications of endocrine disorders. It's a rare condition characterized by the acute/subacute onset of diffuse neuropathic pain and some usually some autonomic dysfunction. And it occurs when you have rapid and substantial reductions in blood glucose levels. And you can almost map it out. There was a study from 2015 which is referenced in the article, which found that a drop in hemoglobin A1c of 2 to 3% over three months confers about a 20% absolute risk of developing this treatment-induced neuropathy of diabetes, and a drop of more than 4%, more than 80% risk. So, very substantial. And then in the other---we see this commonly in patients with diabetic lumbosacral radiculoplexis neuropathy---they have the subacute onset of usually asymmetric pain and weakness in the lower limbs that tends to occur more frequently in patients who have had recent better control of their sugar. We can also see it in the upper limbs too. So, you get a perfect score. Dr Berkowitz, well done. Again, I want to thank you. I want to thank you for such a great issue, a great article to kick off the issue, and a great discussion of the neurology of systemic disease. Today I learned a lot talking today, I learned a lot reading the issue. Really grateful for your leadership of putting it together, pulling together a really great author panel, and I think it will come in handy not just for our junior readers and listeners, but also our more experienced subscribers as well. Dr Berkowitz: Thank you so much. Like I said, it was a big honor to be invited to guest edit this issue. I've read it every three years since I started residency. It's always one of my favorite issues. As you said, a manual for consultative neurology, and I learned a ton from our authors and really appreciate the opportunity to work with you and the amazing Continuum team to bring this from an idea, as you said, probably over a year ago to a printed issue. So, thanks again, Lyell. Dr Jones: Thank you. And again, we've been speaking with Dr Aaron Berkowitz, guest editor of Continuum's most recent issue on the neurology of systemic disease. Please check it out, and thank you to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. Thank you for listening to Continuum Audio.

Erie County Coroner Lyell Cook joins to discuss the cause of death statistics for 2025, along with an explanation of the investigation report issued on the deceased Marchello Woodard.

On this episode, Yvette Benavides shares a reflection on ‘To Absent Friends: Eudora Welty's Correspondence with Frank Lyell' selected and edited by Julia Eichelberger.

Join us as we dig into one of the biggest deceptions in modern science — the myth of uniformitarianism! Eric Hovind, and our guest, Dr. Terry Mortensen, will expose how this idea, first popularized by Charles Lyell in the 1800's, completely rewrote how people view Earth's history, and not for the better. Before Lyell, many great scientists studied the world through the lens of Scripture, recognizing the Bible as the true record of Earth's past. But when Lyell began assuming that “the present is the key to the past,” he planted seeds of doubt that grew into today's evolutionary thinking. His assumptions about ancient rocks didn't just change geology, they helped lead generations away from believing God's Word. We trace how this intellectual rebellion against the Bible took root and continues to shape modern science, culture, and education. With help from the late Milt Marcy's eye-opening book, “Exposing the Hidden Roots of the Evolutionary Agenda: The Emperors Who Had No Clothes,” we'll pull back the curtain on one of history's greatest scientific smokescreens. Don't miss this powerful episode as we uncover how a few flawed ideas about the past set the stage for a full-blown war on biblical truth, and why it's time to return to the real foundation — God's Word.   Watch this Podcast on Video at: https://creationtoday.org/on-demand-classes/the-geological-scam-that-hijacked-science-creation-today-show-450/  Join Eric LIVE each Wednesday at 12 Noon CT for conversations with Experts. You can support this podcast by becoming a Creation Today Partner at CreationToday.org/Partner

On today's program, St. Andrew's Chapel in Sanford, Florida, has refused to reveal the salaries of its pastors—even to its own board of elders. But a new whistleblower report shows that at least three of its pastors receive compensation that's raising eyebrows. We'll take a look. Plus, the use of celebrities to promote causes is not new—but ministries are increasingly turning to social media influencers to tout their missions. We look at their uses—and misuses—plus cautions to consider. And, former SBC professor David Sills drops his defamation suit against the late Jennifer Lyell, who accused him of sexual abuse before her death this summer. Meanwhile, other SBC-related defendants in the case are seeking summary judgment. Finally, we'll have an update on the health of popular speaker Christopher Yuan, who was injured in an accident this week. But first, military chaplains are attempting to leave the Anglican Church in North America en masse.  The producer for today's program is Jeff McIntosh. We get database and other technical support from Stephen DuBarry, Rod Pitzer, and Casey Sudduth. Writers who contributed to today's program include Kim Roberts, Daniel Ritchie, Tony Mator, Diana Chandler, Bob Smietana, Adelle Banks—and you, Warren. A special thanks to Baptist Press for contributing material for this week's podcast. Until next time, may God bless you.

The future of the Mount Lyell mine at Queenstown on Tasmania's west coast could become clearer early next year.

What is the future for the Queenstown mine

Bob talks about his weekend, the No Kings demonstrations, the Army Parade, a study that said Lake Ave between Lyell and Ridge Road is the most unsafe stretch of road in the state, a pause being put on ICE raids at farms, hotels, and restaurants, and a Wall Street Journal story on Iran wanting to stop the war with Israel, Bob reads a Facebook post from a Gold Star mother, talks about Fox News vs. PBS coverage of the Army Parade, and gives an update on the mother of Zy'Jae St. Pierre.

Livestock moving from England to Wales will have to be tested from next month. The Welsh Government says that once the whole of England becomes a restricted zone for the bluetongue disease on the first of July, animals will have to test negative for the disease before they can go into Wales. There have been no cases of bluetongue in Wales, or in Scotland this year. There the government also decided earlier this month that animals should be tested if they're coming from a restricted zone. Earlier this week the Livestock Auctioneers Association warned on this programme that limiting the movement of animals across the boarders would be 'catastrophic'. As the UN Oceans summit in Nice draws to a close, it's hoped that more countries will ratify a High Seas Treaty and so bring it into force. This agreement was made two years ago to put 30% of international waters into marine protected areas by 2030. However even within those areas, bottom trawling is allowed. Bottom trawling is already banned in some English waters and the government is consulting on plans to extend that ban. We speak to Michael Kaiser professor of fisheries conservation at the Lyell centre at Heriot Watt University. All week we've been following the journey from field to bread bin - and today we're at the millers. 85% percent of the wheat used for our bread is grown and milled in the UK. We import about 15 percent of bread wheat from Canada and Germany. We visit a miller in Essex who can trace his milling roots right back to the Domesday book. Presenter = Charlotte Smith Producer = Rebecca Rooney

1. Seth continue his review of Luke 8, examining the parable of the sower.2. No question in the inbox. 3. Seth discusses moral responsibility in affairs.

Emergency treatment may be necessary after a person's first seizure or at the onset of abnormal acute repetitive (cluster) seizures; it is required for status epilepticus. Treatment for these emergencies is dictated by myriad clinical factors and informed by published guidance as well as emerging research.   In this episode, Lyell K. Jones, MD, FAAN, speaks with David G. Vossler, MD, FAAN, FACNS, FAES, author of the article “First Seizures, Acute Repetitive Seizures, and Status Epilepticus,” in the Continuum® February 2025 Epilepsy issue. Dr. Jones is the editor-in-chief of Continuum: Lifelong Learning in Neurology® and is a professor of neurology at Mayo Clinic in Rochester, Minnesota. Dr. Vossler a clinical professor of neurology at the University of Washington School of Medicine in Seattle, Washington. Additional Resources Read the article: First Seizures, Acute Repetitive Seizures, and Status Epilepticus Subscribe to Continuum: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @LyellJ  Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum, the premier topic-based neurology clinical review and CME journal from the American Academy of Neurology. Thank you for joining us on Continuum Audio, which features conversations with Continuum's guest editors and authors who are the leading experts in their fields. Subscribers to the Continuum journal can read the full article or listen to verbatim recordings of the article and have access to exclusive interviews not featured on the podcast. Please visit the link in the episode notes for more information on the article, subscribing to the journal, and how to get CME. Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum: Lifelong Learning in Neurology. Today, I'm interviewing Dr Dave Vossler, who has recently authored an article on emergent seizure management, taking care of patients with the first seizure, acute repetitive seizures, and status epilepticus, which is an article in our latest issue of Continuum covering all topics related to epilepsy. Dr Vossler is a neurologist at the University of Washington, where he's a clinical professor of neurology and has an active clinical and research practice in epileptology. Dr Vossler, welcome. Thank you for joining us today. Why don't you introduce yourself to our listeners? Dr Vossler: Thank you very much for the introduction, Lyell. It's a pleasure to speak with you on this podcast, and I hope to go over a lot of important new information in the management of seizure emergencies. As you said, I'm a clinical professor in neurology at University of Washington, been in medicine for many decades now and have published and done research in this area. So, I'm anxious to give you not only my academic experience, but also talk about my own management of patients with status epilepticus over the last four decades. Dr Jones: Yeah, that's fantastic. And I always appreciate hearing from experienced clinicians, and I think our readers and our listeners do appreciate that voice of clinical expertise. And I'll tell you this is a topic, you know, as a neurologist who doesn't see many patients with acute seizure emergencies in my own practice, I think this is a topic that gives many clinicians, including neurologists, some anxiety. Your article, Dr Vossler, is really chock-full of helpful and clinically relevant considerations in the acute management of seizures. So, you now have the full attention of a huge audience of mostly neurologists. What's the one most important practice change that you would like to see in the care of patients with either first or acute prolonged seizures? Dr Vossler: Without a doubt, the most important clinical takeaway with regard to the status epilepticus---and for status epilepticus, many, many clinical trials, research trials have been done over the last couple decades and they all consistently show the same thing, that by and large most patients who have status epilepticus are underdosed and undertreated and treated too slowly in the initial stages of the status epilepticus. And it's important to use full bolus dosages of benzodiazepines to prevent mortality, morbidity, and later disability of these patients. To prevent the respiratory depression, many physicians are afraid to use higher doses of benzodiazepines, even guideline-recommended doses of benzodiazepines for fear of respiratory depression. But it's actually counterintuitive. It turns out that most cases of respiratory depression are due to inadequate doses and due to the status epilepticus itself. We know there's greater mortality, we know there's greater morbidity and we know that there's greater need for higher dose, subsequent, anti-seizure medications, prolonged status, if we don't use the proper doses. So, we'll kind of go over that a little bit, but that is the one clinical takeaway that I really would like our listeners to have. Dr Jones: Let's follow that thread a little bit. Dave, I know obviously we will speak in hypotheticals here. We're not going to talk about actual patients, but I think we've all been in the clinical situation where you have a patient who comes into the emergency room usually who's actively seizing, unknown history, don't know much about the patient, don't know much about the circumstances of the onset of the seizure. But we now have a patient with prolonged convulsive seizures. How do we walk through that? What are the first steps in the management of that patient? Dr Vossler: Yeah, well, I'll try to be brief for the purposes of the podcast. We do, of course, go through all of that in detail in the Continuum article, which hopefully everybody will look at very carefully. Really in the first table, the very first table of the article, I go through the recommended guideline for the American Epilepsy Society on the management of what we call established status epilepticus. The scenario you're talking about is just exactly that: established status epilepticus. It's not sort of evolving or developing status. We're okay they're having a few seizures and we're kind of getting there. No, this patient is now having evidence of convulsive seizure activity and it's continuing or it's repeated seizures without recovery. And so, the first phase is definitely a benzodiazepine and then the second phase is then a longer-acting bolus of a drug like phosphenotoine, valproic acid or levetiracetam. I could get into the details about dosing of the benzodiazepines, but maybe I'll let you guide me on whether we wanted to get into that kind of detail right at the outset. It's going to be a little bit different. For children, its weight-based dosing, but for adults, whether you use lorazepam or you use diazepam or you use midazolam, the doses are a little bit different. But they are standardized, and gets back to this point that I made earlier, we're acting too slow. We're not getting these patients quick enough, for various reasons, and the doses that are most commonly used are below what the guidelines call for. Dr Jones: That's great to know, and I think it's fine for the details to refer our listeners to the article because there are great details in there about a step-by-step approach to the established status epilepticus. The nomenclature and the definitions have evolved, haven't they, Dr Vossler, over time? Refractory status epilepticus, new-onset refractory status epilepticus, super refractory status epilepticus. Tell us about those entities, how they're distinguished and how you approach those. Dr Vossler: That's an important thing to kind of go over. They- in 2015, the International League Against Epilepsy, ILAE, which is, again, our international organization that guides our understanding of all kinds of things epileptic in nature around the world. In 2015 they put out a definition of status epilepticus, but it used to be that patients had thirty minutes of continuous seizure activity or repetitive obvious motor seizures with impairment of awareness and they don't recover impairment between these seizures. And that goes on for thirty minutes. That was the old definition of status epilepticus. Now, the operational definition is five minutes. And I think that's key to understand that, after five minutes of this kind of overt seizure activity, you need to intervene. And that's what's called T1 in the 2015 guideline, the international guideline. There are a bunch of different axes in the classification of status that talk about semiology, etiology, EEG patterns, and what age group you're talking about. We won't really get into those in the Continuum article because that's really more detailed than a clinician really should be. Needing to think about the stages, what we call the stages of status epilepticus that you mentioned and I alluded to earlier are important. And that is sort of new nomenclature, and I think probably general neurologists and most emergency room physicians aren't familiar with those. So, it just briefly goes through those. Developing status epilepticus is where you're starting- the patient's starting to have more frequent seizures, and it's heading essentially in the wrong direction, if you will. Established status epilepticus, as I mentioned, is, you know, this seizure act, convulsive or major, major outward overt seizure activity lasting five minutes or more, at which time therapy needs to begin. Again, getting back to my point, what doesn't happen often enough is we're not- we're intervening too late. Third is refractory status epilepticus, which refers to status epilepticus which continues despite adequate doses of an initial benzodiazepine given parenterally followed by a full loading dose of a single non-sedating anti-seizure medicine, which today includes phosphenotoine IV valproic acid or IV levetiracetam. In the United States, and increasingly around the world, people really are using levetiracetam. First, it has some advantages. There's now proof from a class one NIH-funded trial. We know that these three drugs are equivalent at the full doses that I go over in the article. You have your kind of dealer's choice on those. Phenobarbital, which we used to use and I used as a resident as long as forty years ago, is really a second choice drug because of its sedating and other side effects. But around the world in resource-poor countries phenobarbital can be used and, in a pinch, certainly is an appropriate drug. And then finally, you mentioned super refractory status epilepticus and that's status that's persisting for more than twenty four hours. Now, despite initial benzo and non-sedating anti-seizure medicine, but also lasting more than twenty four hours while receiving an intravenous infusional sedating, anesthetizing anti-seizure medicine like ketamine, propofol, pentobarbital or midazolam drips. Dr Jones: So, it sounds like the definitions have evolved in a way that improves the outcomes, right? To do earlier identification of status epilepticus and more aggressive management, I think that's a great takeaway. If we move all the way to the other end of the spectrum, let's move to the ambulatory setting and we have a patient who comes in and they've had one seizure, they're an adult; one seizure, the first seizure. The key question is, how do we anticipate the risk of future seizures? But walk us through how you talk to that patient, how you evaluate that patient to decide if and when to start anti-seizure medicines. Dr Vossler: Well, it depends a little bit if it's an adult or a child, but the decision making process and the data behind it is pretty robust now. And the decision making process is pretty similar for adults and children, with some differences which I can talk about. First of all, first seizures. I think it's really important to stress that there's been so much research in this area. I'd like to get a cross point that they're not as innocuous as I think many general neurologists might suspect. We know that there is a two- to threefold increased risk of death in children and adults following a first seizure. Moreover, the risk of a second seizure, both in kids and adults, is about 36% two years after that first seizure. It's about 46% five years after that first seizure. It's really pretty substantial. The risk of a second seizure is increased twofold. It doubled in the presence of any kind of a history of prior brain insults that could result in seizures. Could be infections, it could be a prior stroke, it could be prior significant brain trauma. It's also doubled in the presence of an EEG, which shows epileptiform discharges like spikes and sharp waves---and not just a sort of borderline things like sharply contoured rhythmic Theta activity. That's really not what we're talking about. We're talking about overt epileptiform discharges. It's doubled in the presence of lesion that can be seen on imaging studies, and it's doubled in the presence of seizures if that first seizure occurs during sleep. So, we have a number of things that double the risks, above the risk of a second seizure, above that 36% at two years and 46% at five years that I spoke about. And so those things need to be considered when you're counseling a patient about that. Should you be on an anti-seizure medicine after that first seizure? Specifically, to the point of anti-seizure medications, the guideline that was done, the 2015 guideline that was done by the American Academy of Neurology for adults, and the 2003 guideline was actually a practice parameter that was done by the Academy and the American Epilepsy Society for children, are really kind of out of date. They talk about the adverse effects of anti-seizure medications, but when you look back at the studies that were included in developing that practice parameter for kids and guidelines for adults, they are the old drugs: carbamazepine, phenytoin, phenobarbital and valproate. Well, I don't think I need to tell this audience, this well-educated audience, that we don't use those drugs anymore. We are using more modern anti-seizure medicines that have been developed since 1995; things like lamotrigine, levetiracetam, and lecosamide. Those three in particular have very low adverse events. So, the guideline that the Academy, American Academy Neurology and American Epilepsy Society put together for kids and for adults talks about this high adverse event profile. And so, you need to take a look at the risks that I talked about of a seizure recurrence and balance that against adverse effects. But I'm here to tell you that the newer anti-seizure medicines---and by newer I'm talking in the last thirty years since lamotrigine was approved in 1995---these drugs have much better side effect profiles. And I think all epileptologists would agree with that. They're not necessarily more effective, but they are better tolerated. That makes the discussion of the risk of a second seizure, the risk of mortality versus side effects of drugs, it really pushes the risk category higher on the first side and not on the side of drugs. We know that if you take an anti-seizure medicine, you reduce your risk of a second seizure by half. Now, that's not sustained over five years, but over the first two years, you've reduced it by half. In a person who's driving, needs to get to work, has to take the kids to school, whatever, most of my patients are like, yeah, okay, sign me up. These drugs are really pretty well tolerated. There's a substantial risk of a second seizure. So, I'll do that. In a kid,  a child that's, you know, not driving yet, that might be a different discussion. And the parents might say, well, I'd rather not have my son exposed, my daughter exposed to this. They're trying to go to school. They're trying to learn. We don't want to hinder that. We'll wait for a second seizure and then if they have a second seizure, which by the way is, you know, one of the definitions of epilepsy, well then they have epilepsy, then they probably will need to go on the seizure medication. Dr Jones: Great summary, Dr Vossler, and it is worth our audience being aware that the evidence has evolved alongside the improvement in the adverse effect profile. And sounds like your threshold is a little lower to treat then maybe it would have been some time ago, right? Dr Vossler: I would say that's exactly correct in my opinion. Particularly for adults, absolutely. Dr Jones: That's fantastic, Dr Vossler. I imagine there are a lot of aspects of caring for these patients that are challenging, and I imagine many scenarios are actually pretty rewarding. What do you find the most rewarding aspect of caring for patients with acute seizure management? Dr Vossler: Yes, I mean, that is really true. I would say that the most challenging things are treating refractory status epilepticus, but worse yet, new onset refractory status epilepticus and the super refractory status epilepticus, which I talk extensively about or write extensively about in the article and provide a lot of guidance on. Really, those conditions are so challenging because they can go on for such a long time. Patients are hospitalized for a long time. A lot of really good clinical guidance doesn't exist yet. There is a tremendous amount of research in that area which I find exciting, and really there's an amazing amount of international research on that, I think most of our audience probably is unaware of. And certainly, with those conditions, there is a high risk of later disability and mortality. We go through all of that in the article. The rewards really come from helping these people. When someone was super refractory status and it were non- sorry, new onset refractory status epilepticus, has been in the hospital for thirty days, it gets really hard for everybody; the family, the patient. And for us, it wears on us. Yet when they walk out the door, and I've had these people come back to the epilepsy clinic and see me later. We're managing their anti-seizure medications. They've survived. The NORSE patients often have substantial disability. They have cognitive and memory and even some psychiatric disability. But yet we can help them. It's not just management in the hospital, but it's getting to know these people, and I take them from the hospital and see them in my clinic and manage them long-term. I get a lot of great satisfaction out of that. We're hoping to do even better, stop patients' status early and get them to recover with no sequelae. Dr Jones: What a great visual, seeing those patients who have a devastating problem and they come back to clinic and you get the full circle. And what a great place to end. Dr Vossler, thank you so much for joining us, and thank you for such a thorough and fascinating discussion on the importance of understanding and managing patients with the first seizure, acute repetitive seizures, and status epilepticus. Dr Vossler: Thank you very much, Lyell. Dr Jones: Again, we've been speaking with Dr Dave Vossler, author of an article on emergent seizure management, first seizures, acute repetitive seizures and status epilepticus in Continuum's most recent issue on epilepsy. Please check it out, and thank you to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use this link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

On a misty morning in the fall of 1985, a small group of Haida people blockaded a muddy dirt road on Lyell Island, demanding that the government work with Indigenous people to find a way to protect the land and the future. The Stand is a riveting feature documentary drawn from more than a hundred hours of archival footage from that first blockade and the months that followed. Christopher Auchter, director of the award-winning documentary Now Is The Time, recreates the critical moment when the Haida Nation took a stand to protect their land. The Stand is showing this month in Vancouver and at other locations around BC. We spoke with Christopher Auchter in September last year.

En 1858, Darwin reçoit une lettre d'un jeune naturaliste gallois, Alfred Russel Wallace, qui travaille à Bornéo. Wallace demande l'avis de Darwin sur ses travaux qui - Darwin en tombe de sa chaise -  aboutissent aux même conclusions ! Wallace prie Darwin de transmettre le document, s'il le trouve satisfaisant, à Lyell, un éminent géologue de cette époque (cf épisode 2/8). Darwin est désespéré, aux abois. Faut-il transmettre le texte de Wallace et perdre le bénéfice de 20 ans de travaux ? Faut-il publier ses propres textes en doublant Wallace sans le lui dire ? Darwin, loyal et bienveillant, coupe la poire en deux. Les textes seront présentés comme cosignés et lus devant l'éminente Société linnéenne de Londres. Ce sera le premier séisme scientifique, celui qui annoncer la publication de l'origine des espèces en 1859. Cette publication va faire tomber l'homme du piédestal sur lequel il s'était installé. Une révolution sans précédent depuis la découverte de la gravitation par Newton._______ 

A l'occasion de la Journée mondiale de Darwin, le 12 février, BSG rediffuse une série consacrée au père de la théorie de l'Évolution.Dans cet épisode, l'explorateur Alexander Von Humboldt, le botaniste et entomologiste John Henslow et le géologue Charles Lyell, dont les explorations, les études et les théories ont beaucoup influencé le jeune Darwin.Alexander von Humboldt (1769 - 1859) est le «second découvreur de l'Amérique». Cet allemand, frère intrépide du fondateur de l'université de Berlin, était un mix entre De Vinci et Mike Horn pour faire simple;) Un esprit universel, qui remonté l'Orénoque en pirogue, escaladé le volcan Chimborazo (un volcan très spécial, cf épisodes volcans avec JM Bardintzeff), bravant bien des tempêtes au long cours...John Stevens Henslow obtient en 1822 la chaire de minéralogie de l'université de Cambridge. Ce religieux progressiste se passionne pour la botanique et l'entomologie. Henslow est un professeur très recherché. Son élève Charles Darwin lui doit son intérêt pour l'histoire naturelle. C'est grâce à Henslow que Darwin rencontre le capitaine Robert FitzRoy du HMS Beagle.Le géologue Charles Lyell expose vers 1830 une théorie très controversée: la terre aurait été façonnée lentement, pendant des millions d'années, par des forces toujours existantes (uniformitarisme). Cette vision s'oppose au catastrophisme soutenu par Cuvier. Selon le Français, la Terre avait été modelée par une série de catastrophes, tel le déluge, dans un laps de temps court. Cuvier was wrong... Lyell, ami proche de Charles Darwin, est l'un des premiers scientifiques reconnus à apporter son appui à L'Origine des espèces, à une époque où Darwin essuyait une grosse shitstorm...Jean-Claude Simard est  professeur de philosophie et chercheur à l'Université du Québec à Montréal, et un grand connaisseur de la vie de Charles Darwin.Sur la photo: Alexander Von Humboldt_______

On our Wednesday health focus, Coroner Lyell Cook returned to The Joel Natalie Show with some good news: fentanyl deaths in Erie County were down last year.

Bob talks about the terror attacks, takes calls, talks about H1B visas, the arrest of Anthony Hall, the terror attack in Las Vegas, the anniversary of the Kodak Center attack, Claudia Tenney in Puerto Rico, and a hit and run on Lyell and Child.

Our guest is Reggie Lyell, MD, medical director of informatics at Baptist Health. Dr. Lyell discusses the near-death experience that caused him to retire and the opportunity that inspired him to return to work. He talks about his new role as a leader focused on improving clinical workflows and his current project to improve the in-basket experience. American Medical Association CXO Todd Unger hosts.

Episode: 1260 Darwin boards the Beagle and sails into history.  Today, a young man boards a ship and redirects history.

Chris is a successful entrepreneur whose resume includes successful ventures in marketing, import/export, Brand Creation, and consulting. Over the years, he has built and sold several companies while also assisting numerous brands in achieving rapid growth on Amazon. Currently, he is a seven-figure Amazon seller and a consultant for multiple companies, specializing in brand protection on the platform.Highlight Bullets> Here's a glimpse of what you would learn…. Strategies for enforcing intellectual property (IP) rights on Amazon.Challenges faced by seven-figure Amazon sellers, including rising fees and competition.The impact of resellers and hijackers on brand integrity and pricing.Opportunities and challenges of selling through retail channels, such as Walmart.The importance of a robust IP protection strategy, including trademarks and patents.The Amazon Transparency Program and its role in preventing counterfeiting.Protecting Minimum Advertised Price (MAP) across multiple sales channels.Recommendations for developing a comprehensive IP protection strategy.The significance of monitoring and addressing unauthorized sellers on Amazon.Resources and tools for enhancing e-commerce operations and brand protection.In this episode of the Ecomm Breakthrough Podcast, hosted by Josh Hadley, Chris Lyell shares strategies for enforcing intellectual property (IP) rights on Amazon, protecting brands from hijackers and resellers, and overcoming challenges faced by seven-figure Amazon sellers. Chris discusses the importance of Amazon's Transparency Program to combat counterfeit products and protect listings. He also highlights the complexities of maintaining Minimum Advertised Price (MAP) across multiple sales channels and offers actionable advice for developing a robust IP protection strategy. The episode provides valuable insights for business owners aiming to scale their e-commerce operations and safeguard their brands.Here are the 3 action items that Josh identified from this episode:Develop a Comprehensive IP Protection StrategyInclude trademarks, copyrights, and patents to reduce competition.Utilize Brokers and Industry ContactsNavigate retail opportunities effectively with the help of experienced brokers.Implement a Robust Monitoring StrategyProtect Amazon listings from unauthorized sellers, especially after entering retail channels.Resources mentioned in this episode:Josh Hadley on LinkedIneComm Breakthrough ConsultingeComm Breakthrough PodcastEmail Josh Hadley: Josh@eCommBreakthrough.comAmazon APEX ProgramFaireAmazon Brand RegistryAmazon Report Violation ToolAmazon Transparency ProgramAveryOpenAI / ChatGPTData DiveBillion Dollar Seller SummitTools of TitansSpecial Mention(s):Adam “Heist” Runquist on LinkedInKevin King on LinkedInMichael E. Gerber on LinkedInRelated Episode(s):“Cracking the Amazon Code: Learn From Adam Heist's Brand Scaling Secrets” on the eComm Breakthrough Podcast“Kevin King's Wicked-Smart Tips for Building an Audience of Raving Fans” on the eComm Breakthrough Podcast“Unlocking Entrepreneurial Greatness | Insider Secrets With E-myth Author Michael Gerber” on the eComm Breakthrough PodcastEpisode SponsorThis episode is brought to you by eComm Breakthrough Consulting where I help seven-figure e-commerce owners grow to eight figures. I started Hadley Designs in 2015 and grew it to an eight-figure brand in seven years.I made mistakes along the way that made the path to eight figures longer. At times I doubted whether our business could even survive and become a real brand. I wish I would have had a guide to help me grow faster and avoid the stumbling blocks.If you've hit a plateau and want to know the next steps to take your business to the next level, then go to www.EcommBreakthrough.com (that's Ecomm with two M's) to learn more.Transcript AreaJosh Hadley 00:00:00  Welcome to the Ecomm Breakthrough podcast. I'm your host, Josh Hadley, where I interview the top business leaders in e-commerce. Past guests include Kevin King, Aaron Cordovez and Michael Gerber, author of the E-myth. Today I'm speaking with Chris Lyell, and we're going to be talking about how you can enforce your rights on Amazon to not only protect your IP, your intellectual property, but how you can create a digital moat around your business to protect you from hijackers, resellers and all that good stuff. This episode is brought to you by Ecomm Breakthrough, where I specialize in investing in and scaling seven figure companies to eight figures and beyond. If you're an ambitious entrepreneur and looking for a partner who can help take your business to the next level, my team and I bring that hands-on experience, the strategic insights, and the resources ready to fuel your growth. So if you or someone you know is ready to scale and looking for an investment partner, reach out to me directly at Josh at Ecomm Breakthrough dot com. That's ecom with two M's and let's turn your dreams into reality.Josh Hadley 00...

On a misty morning in the fall of 1985, a small group of Haida people blockaded a muddy dirt road on Lyell Island, demanding that the government work with Indigenous people to find a way to protect the land and the future. The Stand is a riveting new feature documentary drawn from more than a hundred hours of archival footage from that first blockade and the months that followed. We speak with director Christopher Auchter.

On this week's Biotech Hangout, hosts Daphne Zohar, Brad Loncar, Josh Schimmer, Tim Opler and Chris Garabedian open up with a conversation on recent trends in M&A for private biotechs versus public companies and the potential impact of the election year. The hosts also cover the important data readouts from the week, including Alnylam's positive Phase 3 results for its ATTR drug and Lyell's report of a patient death in its early-stage CAR T trial. Additional data covered includes Wave's Huntington data readout, Intellia's redosing of CRISPR gene editing therapy and Savara's Phase 3 readout in rare lung disease. In financing news, the hosts recap Curie.bio's $380M Pro Rata Series A Fund, Formation's $372M Series D and Recursion's $200M offering. This leads into a conversation on AI in drug development and how this is an area full of both promise and hype. On the management theme, the group discusses Gingko's recent layoffs, business model & revenues. Rounding out the show on the management theme, Amylyx's pivot to license GLP-1 was mentioned as an example of a management team earning credibility for following through on their word. *This episode aired on June 28, 2024.

Vivimos en un mundo en el que las ciencias son de nicho y las letras, de multitudes. Mucha gente ha leído el Quijote, pero muy poca ha leído los Principia de Newton o los Elementos de Euclides. ¿Somos, pues, una sociedad de letras? ¿A qué se debe? ¿Y cómo podemos remediarlo? En el programa de hoy, el historiador de la ciencia José Manuel Sánchez Ron nos propone un viaje por las grandes obras maestras de la historia de la ciencia. Será difícil que leamos los Principios de Geología de Lyell o La Naturaleza del Enlace Químico de Pauling si ni siquiera los conocemos. Para remediar esto, Sánchez Ron ha escrito "El canon oculto", un libro en el que recopila las 100 obras científicas que todos deberíamos conocer si no queremos ser unos auténticos incultos. Porque la ciencia, como empeño humano que es, también es cultura. Al profesor Sánchez Ron ya lo tuvimos en el programa, en su faceta de académico de la lengua, hablando sobre las palabras científicas del Diccionario de la RAE. Si queréis repasarlo buscad el capítulo s04e17. Este programa se emitió originalmente el 18 de abril de 2024. Podéis escuchar el resto de audios de Más de Uno en la app de Onda Cero y en su web, ondacero.es

We were very fortunate to have LYELL on the podcast to talk about her new single, "Lighthouse". Enjoy! LYELL Socials: Twitter: https://twitter.com/LYELLgirl Instagram: https://www.instagram.com/lyellgirl/ Facebook: https://www.facebook.com/lyellgirl/ TikTok: https://www.tiktok.com/@lyellgirl YouTube: https://www.youtube.com/@lyellgirl Apple Music: https://music.apple.com/us/artist/lyell/1561651445 Spotify: https://open.spotify.com/artist/3aDih8lIm5GOfAaorpUg5Y Grab some GNP Merch!: https://goodnoisepodcast.creator-spring.com/ Check out the recording gear we use: https://www.amazon.com/shop/goodnoisepodcast Support the show on Patreon: https://www.patreon.com/goodnoisepodcast Good Noise Podcast Socials: Twitter: https://twitter.com/good_noise_cast Instagram: https://www.instagram.com/goodnoisepodcast/ Facebook: https://www.facebook.com/goodnoisepod Discord: https://discord.gg/nDAQKwT YouTube: https://www.youtube.com/channel/UCFHKPdUxxe1MaGNWoFtjoJA Spotify: https://open.spotify.com/show/04IMtdIrCIvbIr7g6ttZHi All other streaming platforms: https://linktr.ee/goodnoisepodcast Bandcamp: https://goodnoiserecords.bandcamp.com/

On today's episode of Online Store Success, I chat with Rosie, the owner of The Happy Folk, who shares her success story selling on Etsy. She started by making her own body scrubs and candles and eventually expanded to gift boxes. Rosie found success on Etsy, primarily selling to customers in Australia. She credits her success to her creativity and the support she received in my Online Store Success course (thank you, Rosie!) Rosie's favourite part of running her business is making candles and putting together gift boxes. She advises aspiring entrepreneurs to keep trying and be patient. Follow Rosie at The Happy Folk here: Etsy store Website Instagram Visit the full podcast episode page here: Visit my full website here: Learn about the program Rosie did with me here. Online Store Success

Head over to dealfront.com and sign up for a 14-day (no strings attached) free trial Startup Wise Guys is a diverse team of tech lovers, mentors, experts, and founders ourselves, bound together by our passion to support founders on their entrepreneurial journey. They're a startup accelerator like no other. Our optimized approach puts early-stage startups on the map and catapults them into worldwide success. Startup Wise Guy's origins began in Europe's tech-savvy startup capital, Estonia. It's the most experienced accelerator fund in the region with over 35+ programs, an international community of founders from over 60 countries, and an established market in CEE and CIS countries. Connect with Billy

This week, we're scratching The Itch for an intermission! When we last left our heroes, The Itch was at halfway through recapping our Shiprocked adventure. Eva Under Fire had an adventure of their own at this point in the story, so this week vocalist and part-time Itch co-host Eva Marie joins us to discuss Shiprocked from the artists' perspective. We'll hear tales of soundchecks gone awry, wholesome singalongs, and staying ready so you don't have to get ready. Plus, Eva discusses her new collaboration with Lyell and Hyro the Hero, and The Itch discovers the real princess in Eva Under Fire... Hint: It's not her. We'll be back next week to (maybe) wrap up this year's Shiprocked coverage. In the meantime, if you're in the Detroit area on March 1st, Eva Under Fire and The Itch would love to see you at the premiere of Eva's film, My Rockstar, at The Crofoot. If you or someone you loved have experienced the pain of addiction, this night is for you to feel seen and loved. If you like what you hear, you can hear more of us every Sunday night broadcasting rock to the masses from 6-9pm CST on KCLC-FM. If you're not in the St. Louis area, you can stream the show from 891thewood.com, TuneIn, Radio.net, and OnlineRadioBox! And if you have the itch to hear brand new rock tracks every Friday, follow our New Rock Roundup playlist! For any and all friendship, questions, inquiries, and offers of pizza, The Itch can be found at the following: Website: itchrocks.com Twitter: Twitter.com/itchrocks Facebook: Facebook.com/itchrocks Instagram: Instagram.com/itchrocks Email: itchrocks@gmail.com Thank you so much for listening. If you like what you hear, please subscribe and leave a positive review and rating on Apple Podcasts or Podchaser to help our audience grow. If you don't like what you hear, please tell us anyway to help our skills grow. Our theme song "Corrupted", is used with permission from the amazing Skindred. All other content is copyright of The Itch. All rights reserved, including the right to rock on.

The Erie County Coroner Lyell Cook joined us Tuesday to review the preliminary statistics regarding investigated deaths his office handled in 2023, including the highest number of homocides in 50 years.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Bruce Thompson, CEO of Kincell Bio. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Bruce, covering: The daunting and exciting prospect of launching a CDMO spin-out focused on early-phase companies The challenges and opportunities of pivoting a facility from innovator-owned to CDMO-owned Navigating from technical leader to a first CEO role... and the importance of covering your blind spots Why Bruce is seeing an upturn in the market and the emergence of more diverse opportunities.   Bruce is the CEO of Kincell Bio, bringing over 28 years of experience to his position. Before this, he was Vice President and Technical Lead for the Cell Therapy Franchise at Resilience, Inc., where he helped build the development and GMP manufacturing capabilities and served as a technical advisor internally and externally. He has over 18 years of CMC strategy, product development, and cell therapy manufacturing experience. In his first startup role, he was Vice President of Process Sciences at Lyell Immunopharma, where he was responsible for Process and Analytical Development and tech transfer of processes and methods to a newly built state-of-the-art cGMP facility. Prior to Lyell, Bruce served as the Sr. Director of the Therapeutic Products Program at Fred Hutchinson Cancer Research Center (FHCRC), where he led GMP manufacturing of cell and gene therapy products. He was responsible for supporting >15 active clinical programs and contributed to the filing of 6 INDs for various cell therapy programs. Bruce also spent nearly ten years at Pfizer in the Pharmaceutical Sciences division, and he received his B.A. in Biology, an M.S. in Biochemistry from The Ohio State University, and a Ph.D. in Microbiology and Immunology from the University of Louisville. Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed, and grow in life sciences.  

This is the fourth part in a series on artificial intelligence in medicine and we try and unpick the causes and consequences of adverse events resulting from this technology. Our guest David Lyell is a research fellow at the Australian Institute of Health Innovation (Macquarie University) who has published a first-of-its kind audit of adverse events reported to the US regulator, the Federal Drugs Administration. He breaks down those that were caused by errors in the machine learning algorithm, other aspects of a device or even user error.   We also discuss where these all fit in to the four stages of human information processing, and whether this can inform determinations about liability. Uncertainty around the medicolegal aspects of AI-assisted care is of the main reasons that practitioners report discomfort about the use of this technology. It's a question that hasn't been well tested yet in the courts, though according to academic lawyer Rita Matulonyte, AI-enhanced devices don't change the scope of care that has been expected of practitioners in the past. Guests>Rita Matuolynte PhD (Macquarie Law School, Macquarie University; ARC Centre of Excellence for Automated Decision Making and Society; MQ Research Centre for Agency, Values and Ethics)>David Lyell PhD (Australian Institute of Health Innovation, Macquarie University; owner Future Echoes Business Solutions) ProductionProduced by Mic Cavazzini DPhil. Music licenced from Epidemic Sound includes ‘Kryptonite' by Blue Steel and ‘Illusory Motion' by Gavin Luke. Music courtesy of Free Music Archive includes ‘Impulsing' by Borrtex. Image by EMS-Forster-Productions licenced from Getty Images. Editorial feedback kindly provided by physicians David Arroyo, Stephen Bacchi, Aidan Tan, Ronaldo Piovezan and Rahul Barmanray and RACP staff Natasa Lazarevic PhD. Key References More than algorithms: an analysis of safety events involving ML-enabled medical devices reported to the FDA [Lyell, J Am Med Inform Assoc. 2023]How machine learning is embedded to support clinician decision making: an analysis of FDA-approved medical devices [Lyell, BMJ Health Care Inform. 2021]Should AI-enabled medical devices be explainable? [Matulonyte, Int J Law Inform Tech. 2022]Please visit the Pomegranate Health web page for a transcript and supporting references. Login to MyCPD to record listening and reading as a prefilled learning activity. Subscribe to new episode email alerts or search for ‘Pomegranate Health' in Apple Podcasts, Spotify, Castbox or any podcasting app. 

In this inspiring episode of Behind the Lens, we're thrilled to feature David Lyell, a USPSA Grandmaster, Multi-Time USPSA SC State Champion, and now, the new Product Line Manager for the DS Platform at MasterPiece Arms (MPA). Join us as host Brian Conley delves into the intersection of Lyell's esteemed competitive shooting career and his new responsibilities at MPA. Our conversation explores his extensive experience with MPA equipment, his winning strategies, and his vision for the future of shooting sports equipment.Regardless of where you are in your shooting journey, this episode offers a unique blend of competitive insight and industry expertise, making it a must-listen. Lyell's impressive career in shooting sports and his recent transition to a key role at MPA make this a captivating conversation that you won't want to miss. Discover the world of competitive shooting sports through the eyes of industry leaders, top athletes, and match directors in the Behind the Lens Podcast, hosted by Brian Conley of Hunters HD Gold. Join us as we explore the dynamic world of competitive shooting, the shooting industry, and the remarkable individuals who make it all possible. Hunters HD Gold Behind the Lens Podcast Now in its third season!Discover the world of competitive shooting sports through the eyes of industry leaders, top athletes, and match directors in the Behind the Lens Podcast, hosted by Brian Conley of Hunters HD Gold. Delve into captivating conversations that reveal the passion, dedication, and skill that define the shooting sports community. Brian, a steadfast supporter of the shooting sports, brings unique insights and expertise to each episode. Uncover the latest trends, techniques, and stories from the people who shape the shooting sports landscape. Join us as we explore the dynamic world of competitive shooting, the shooting industry, and the remarkable individuals who make it all possible.Hunters HD Gold Links:Website: https://huntershdgold.comInstagram: https://www.instagram.com/huntershdgold/Facebook: https://www.facebook.com/HuntersHDGoldYouTube: https://www.youtube.com/channel/UCBWH4kOqaX-x34uYOviQ-tgUnited States Practical Shooting Association Official Eyewear: https://uspsa.orgSteel Challenge Shooting Association Official Eyewear: https://scsa.orgMetal Madness Official Eyewear: https://...

In this inspiring episode of Behind the Lens, we're thrilled to feature David Lyell, a USPSA Grandmaster, Multi-Time USPSA SC State Champion, and now, the new Product Line Manager for the DS Platform at MasterPiece Arms (MPA). Join us as host Brian Conley delves into the intersection of Lyell's esteemed competitive shooting career and his new responsibilities at MPA. Our conversation explores his extensive experience with MPA equipment, his winning strategies, and his vision for the future of shooting sports equipment.Regardless of where you are in your shooting journey, this episode offers a unique blend of competitive insight and industry expertise, making it a must-listen. Lyell's impressive career in shooting sports and his recent transition to a key role at MPA make this a captivating conversation that you won't want to miss. Discover the world of competitive shooting sports through the eyes of industry leaders, top athletes, and match directors in the Behind the Lens Podcast, hosted by Brian Conley of Hunters HD Gold. Join us as we explore the dynamic world of competitive shooting, the shooting industry, and the remarkable individuals who make it all possible. Hunters HD Gold Behind the Lens Podcast Now in its third season!Discover the world of competitive shooting sports through the eyes of industry leaders, top athletes, and match directors in the Behind the Lens Podcast, hosted by Brian Conley of Hunters HD Gold. Delve into captivating conversations that reveal the passion, dedication, and skill that define the shooting sports community. Brian, a steadfast supporter of the shooting sports, brings unique insights and expertise to each episode. Uncover the latest trends, techniques, and stories from the people who shape the shooting sports landscape. Join us as we explore the dynamic world of competitive shooting, the shooting industry, and the remarkable individuals who make it all possible.Hunters HD Gold Links:Website: https://huntershdgold.comInstagram: https://www.instagram.com/huntershdgold/Facebook: https://www.facebook.com/HuntersHDGoldYouTube: https://www.youtube.com/channel/UCBWH4kOqaX-x34uYOviQ-tgUnited States Practical Shooting Association Official Eyewear: https://uspsa.orgSteel Challenge Shooting Association Official Eyewear: https://scsa.orgMetal Madness Official Eyewear: https://...

Omar Ali is the Senior Director of Research at Lyell Immunopharma. Omar discusses leadership lessons he's picked up across 2 decades working at the intersection of bioengineering and drug development. Starting his first company during grad school at Harvard. Afterwards spending ~7 years at the Wyss Institute for Biologically Inspired Engineering. Setting up his second startup, Immulus, focused on immune cell expansion. That was acquired by Lyell. Omar is an expert in a wide-range of fields from biomaterials and immunotherapy to drug deliver, cancer vaccines, and chemistry; however, his superpower is managing interdisciplinary teams and leadership.

Synopsis: Gary Lee, Ph.D. is the CSO of Lyell Immunopharma, a T-cell reprogramming company dedicated to developing cell therapies for patients with solid tumors. A chemical engineer by training, Gary has been working in the gene therapy field for 20+ years. He discusses how he's observed the cell therapy space evolve over the last couple of decades. He talks about the work his team is doing to develop effective cell-based therapies for solid tumor cancers and where they are from a development and team-building perspective. He also provides his perspective on opportunities he sees for future technology across the cell therapy landscape. Biography: Gary Lee, Ph.D., has served as our Chief Scientific Officer since January 2022. Dr. Lee is a veteran biotech executive with over a decade of experience leading cell and gene therapy programs for human applications. From October 2018 to January 2022, Dr. Lee was the Chief Scientific Officer at Senti Bio. From August 2005 to October 2018, Dr. Lee held positions of increasing scientific and leadership responsibility at Sangamo Therapeutics, including last as the Vice President of Cell Therapy. Dr. Lee earned his Ph.D. in Chemical Engineering from the University of California, Berkeley, and his B.S. in Chemical Engineering from the California Institute of Technology.

What's a IPA again Roc?!?!Rocco and Archie breakdown some of their favorite beers and whiskey.----------------------------------NEW SEVENDUST Song "FENCE"https://www.youtube.com/watch?v=NixNsandZ34NEW Foo Fighters Song "Rescued"https://www.youtube.com/watch?v=j3S8wdJhgacNEW STAIND Song "Lowest In Mehttps://www.youtube.com/watch?v=kKqdFvW--eM----------------------------------If Lzzy Hale from Halestorm, Fiona Apple, Lana Del Rey and Alison Mosshart from The Dead Weather were sitting at a table discussing the future of Pop Rock....Our next guest would be the topic of conversation!Welcome to NTTFG Podcast, musical artist, LYELL!https://linktr.ee/LyellgirlGiver her a follow, she's DOPE!** SUBSCRIBE TO HEAR MORE NONSENSE**Not These Two Fucking Guys PodcastVideo Episodes:YT: https://www.youtube.com/channel/UC6-fGNWWrjlo1sIPTA_YwOwnttfgpod.comIG: https://www.instagram.com/nttfgpod/Apple: https://podcasts.apple.com/us/podcast/not-these-two-f-g-guys/id1500220870Spotify: https://open.spotify.com/show/1YY78TWStOfO2Pds8dSqjs?si=fac3556401f44500

Dr. Tina Albertson is the Chief Medical Officer and Head of Development at Lyell, using cell therapy to fight solid tumors through epigenetic and genetic reprogramming methods. Tumors have their own mechanisms for suppressing the immune system. These are the types of pathways Lyell is targeting with their engineering to find ways to counter the exhaustion that the T cells exhibit so that T cells can stay functional and kill the solid tumor cells. Tina explains, "Our cell therapies are from the patient's own cells, so these are what we call autologous cell therapies. We take the cells from the patient and bring them, in our case to Seattle, to our manufacturing facility. We both genetically and epigenetically reprogram them during manufacturing so that the cells will be resistant to the suppressive microenvironment of the solid tumors."  " I think most people are familiar with the concept of stem cells, which can self-renew as well as make cells that are functional and can differentiate. So when we reprogram them, we make them more stem-like, and this allows us to infuse cells into the patient that should be more persistent and more functional."  "The second product we're also testing in trials is tumor infiltrating lymphocytes or TILs. This is a product where you need a piece of their cancer or their tumor and extract the T cells from the tumor itself. That requires surgery, then a piece of tissue is also sent to our manufacturing facility. Those T cells are extracted and expanded. That takes a little bit longer. But similarly, once those are expanded to the right cell number, we send them back to the site to be reinfused into the patient." #Lyell #CellTherapy #SolidTumors #Oncology #Cancer #TCells #TCellExhaustion #AutologousCellTherapy lyell.com Download the transcript here

Dr. Tina Albertson is the Chief Medical Officer and Head of Development at Lyell, using cell therapy to fight solid tumors through epigenetic and genetic reprogramming methods. Tumors have their own mechanisms for suppressing the immune system. These are the types of pathways Lyell is targeting with their engineering to find ways to counter the exhaustion that the T cells exhibit so that T cells can stay functional and kill the solid tumor cells. Tina explains, "Our cell therapies are from the patient's own cells, so these are what we call autologous cell therapies. We take the cells from the patient and bring them, in our case to Seattle, to our manufacturing facility. We both genetically and epigenetically reprogram them during manufacturing so that the cells will be resistant to the suppressive microenvironment of the solid tumors."  " I think most people are familiar with the concept of stem cells, which can self-renew as well as make cells that are functional and can differentiate. So when we reprogram them, we make them more stem-like, and this allows us to infuse cells into the patient that should be more persistent and more functional."  "The second product we're also testing in trials is tumor infiltrating lymphocytes or TILs. This is a product where you need a piece of their cancer or their tumor and extract the T cells from the tumor itself. That requires surgery, then a piece of tissue is also sent to our manufacturing facility. Those T cells are extracted and expanded. That takes a little bit longer. But similarly, once those are expanded to the right cell number, we send them back to the site to be reinfused into the patient." #Lyell #CellTherapy #SolidTumors #Oncology #Cancer #TCells #TCellExhaustion #AutologousCellTherapy lyell.com Listen to the podcast here

“There's a real diversity of jobs available that folks don't always think about initially when they think about going into healthcare,” says Marc Cummings, the President and CEO of Life Science Washington, a nonprofit trade association serving the life sciences industry in the state of Washington. Dr. Tina Albertson, the Chief Medical Officer at nearby Lyell Immunopharma, agrees. For instance at her company, which does R&D on cell therapies for solid tumor cancers, there's a need for specialists in logistics who organize and monitor the movement of patient cells that need to be flown to other locations to be genetically engineered and returned to the bedside for use in treatment. As these industry veterans share with host Michael Carrese, the Seattle region is a well-established hub in the growing biotech sector due to a unique blend of strengths including longstanding non-profit research institutions and powerhouse tech companies such as Microsoft and Amazon. “This region is really well-prepared for innovation from a basic science standpoint and also from the tech side of our community,” says Albertson. Check out this revealing discussion of the challenges and opportunities in life sciences, the critical role AI and machine learning is now playing, and what they wish more people understood about clinical trials and drug development. Mentioned in this episode: https://lyell.com/https://lifesciencewa.org/

EPISODE NOTES: Every year, one of the biggest parties in the United States takes place in the 300-year-old streets of New Orleans. This episode traces the history of Mardi Gras and its costuming practices in New Orleans up to the twentieth century. Support us at :https://www.patreon.com/historyunhemmedhttps://anchor.fm/historyunhemmed/support Follow us on: Instagram: @history_unhemmed Facebook: History Unhemmed Thank you!

A fun conversation with another one of the brains behind STL's favorite soccer pub, Amsterdam Tavern, Jeff Lyell! We had THE Michael Duggan join us for the accent, his Liverpool take, and to get a transplants opinion on the STL soccer scene and it's future.

On this episode, Erie County Coroner Lyell Cook goes into details about the main causes of death in 2022 and more!

David and I spoke on Twitter Spaces in July 2022. We discussed Eastern Catholic theology and its parallels with Buddhism. We discuss the origin of the word physis (from which "physics"), as well as the history of geology and anthropology, the conversion of the Roman Empire to Christianity, catastrophism vs uniformitarianism, and other topics in complexity. Also mentioned: Darwin, Lyell, Spinoza, Geertz, Tolstoy, Orwell, Shakespeare, Tanya Luhrmann, David Graeber, Jacques Elull, Viktor Shklovsky, Draper & White, Thomas Kuhn, John McPhee, Andrea Wulf, Daniel Kehlmann, William Whewell, and Lev Shestov

Professor Lyell Asher is the creator of the popular video series, “Why Colleges Are Becoming Cults,” where he gives an analysis of university academics and culture in the 20th and 21st centuries. One part of Asher's critique is focused on the effect of the embrace of “whole language” in lieu of phonics in schools of education and its deleterious effect on reading instruction. Asher received his PhD at University of Virginia and is associate professor of English at Lewis & Clark College in Portland, Oregon. You can find his video series on YouTube at https://tinyurl.com/3f7rcydp

This week on The Knight Tube, Stephen Knight (@Gspellchecker) is joined by Dr. Lyell Asher. Dr. Asher is an American English teacher and has become increasingly concerned about the stifling of free expression on American campuses and the spread of illiberal ideologies. He's recently fronted a documentary titled ‘Why colleges are becoming cults' which can be found on YouTube. You can watch the video version of this interview on YouTube: www.youtube.com/gspellchecker Watch ‘Why colleges are becoming cults' on YouTube here: https://www.youtube.com/watch?v=aAqDwn_Q-QQ 0:00 Intro 0:18 About Dr Lyell Asher 2:13 Why take the risk of speaking up publicly? 5:28 Which incidents inspired action? 08:37 The ‘N-word' and a focus on ‘impact' over ‘intention'. 15:31 How are you defining ‘woke'? 19:53 Why is progress not being acknowledged? Why is there a new obsession with race? 25:56 Why are students imposing speech codes and illiberal ideology on themselves? 30:49 How do we know we aren't just grumpy old men that need to get with it? 36:31 Do you use social media? 38:16 Authoritarian tactics and redefining words as violence. 42:03 Have the right taken ownership of defending free speech? 46:32 American speech rights compared to UK ‘hate speech' laws. 52:19 The importance of which method of reading is taught in schools. Support the podcast at http://www.patreon.com/gspellchecker Also available on iTunes, Stitcher, YouTube & Spotify.    

First, please listen to Dr. Lyell Asher's video, Why Colleges Are Becoming Cults. Then come back to hear more about the low quality of ed schools, the supply of racism not meeting demand, how supporting free speech is an “employment killer", cowardly Boards of Directors, tenure, race as a distraction from class, administrative bloat, and grade inflation. Plus, Nina reveals her plans to kill trans people by inviting them on long bike rides when they're out of shape, and Corinna wishes there were more Marxists. Why Colleges Are Becoming Cults [Full Series] | Dr. Lyell Asher https://youtu.be/0hybqg81n-M Bullshit Jobs by David Graeber https://www.rentabasicauniversal.es/wp-content/uploads/2018/09/Bullshit-Jobs_-A-Theory-David-Graeber.pdf Woke, Inc. https://www.vivekramaswamy.com/wokeinc Rob Henderson - Luxury Beliefs https://nypost.com/2019/08/17/luxury-beliefs-are-the-latest-status-symbol-for-rich-americans/ Nina's Open Letter to the U of I https://blog.ninapaley.com/2019/02/28/open-letter-to-the-university-of-illinois/ FIRE: https://www.thefire.org/ Gibson's Bakery v. Oberlin College https://en.wikipedia.org/wiki/Gibson%27s_Bakery_v._Oberlin_College Nina's TERFening https://blog.ninapaley.com/2017/03/22/the-terfening-online-silencing-campaign/ How Ed Schools Became a Menace to Higher Education - https://quillette.com/2019/03/06/how-ed-schools-became-a-menace-to-higher-education/ Low Definition in Higher Education - https://theamericanscholar.org/low-definition-in-higher-education/ --- Support this podcast: https://anchor.fm/heterodorx/support

On Wednesday, we faced a tough subject. Erie has seen a steep increase in fentanyl usage, and the unpredictable drug is causing too many overdoses and deaths. Erie County Coroner Lyell Cook came to our State Street studios to share the local data, and his perspective on this very troubling drug usage epidemic.

Support the show: http://dollarinthejar.com On this week's episode, Ruben Jay welcomes singer and rocker Lyell to the show,  During their conversation, Ruben asks Lyell about:  Her career Touring with Daughtry and Tremonti New music Her creative strategy TUNE IN! 

Dr Daphne Lyell is a homoeopath and integrative GP with a special interest in all things related to women's health, child health, gut health, and diet. She focuses on health and building resilience instead of fighting disease. Dr Lyell also has a particular interest in the birth process and the transformative postpartum period. She has a keen interest in educating and empowering parents. She helps equip them with the knowledge to treat their kids at home. In this episode, we get to know Dr Lyell a little better, her call to integrative medicine, her focus on women and children, as well as her upcoming Holistic Child Health 101 Course. She has created Homeopathic kits to complement the course, or to be used by parents simply interested in being self-reliant. I am so honoured to have this chat with Dr Lyell as I saw her as a patient years ago at the beginning of my own health care journey. I can personally attest she is a doctor with remarkable empathy and compassion. She truly cares about each patient individually and is passionate about effective and holistic approaches to getting their body and mind health back on track in an achievable manner. For more about Dr Daphne Lyell, visit her website at https://drdaphnelyell.co.za/ Find her on Instagram at https://www.instagram.com/dr_daphne_lyell/ --- Support this podcast: https://anchor.fm/christina-masureik/support

On this episode of Manny Talks Shooting we sit down with the "Mad Scientist" David Lyell. David is a Master class USPSA open division shooter out of the SC/ Georgia area. David is a machinist by trade who just started with MasterPiece Arms to help oversee the competition pistol line of products. During the episode we talk about he got started with MasterPiece Arms, his shooting journey, his time as a Match Director, and much much more. Check out David @ https://www.instagram.com/csrashooters/?hl=en https://www.youtube.com/channel/UCFwhpH5A0RRu065UrR6nw5A Check out the podcast "Manny Talks Shooting". Wherever you listen to podcasts. Apple Podcasts: https://podcasts.apple.com/us/podcast/manny-talks-shooting/id1552710518 Anchor: https://anchor.fm/alex-mansfield Manny Things Merch: Follow us on: https://linktr.ee/Mannythings Instagram: https://www.instagram.com/mannythings_/ Email: manny.things@yahoo.com Music courtesy of Ben Sound at https://www.bensound.com